Silence Therapeutics plc (SLNCF)
PNK · Biotechnology
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases. It also develops Zerlasiran (SLN360) for cardiovascular disease associated with elevated lipoprotein(a); SLN312 for dyslipidemia; SLN365 for hypercholesterolemia; and SLN098 for obesity. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, United Kingdom.
Peers in Healthcare
Silence Therapeutics plc has no peer companies in this window.
Recent press releases
Silence Therapeutics plc has not issued a press release in this window.
SEC filings
All filings →Silence Therapeutics plc has not filed an SEC document in this window.
Insider trades
All insider trades →Silence Therapeutics plc has no reported insider trades in the last 90 days.
Institutional holders
All holders →People at Silence Therapeutics plc
All people →No officers or directors have been indexed for Silence Therapeutics plc.